Designation: Assistant Professor
Department: Neurogenetics and Integrated Genomics
University: Andover Innovative Meidinces (AiM) Institute
Country: United States
Dr. Gyungah Jun earned her Ph.D. in Genetic Epidemiology from Case Western Reserve University in 2008. She got two Masters in Microbiology/Immunology at Seoul National University in Korea and Computer and Information Science at Cleveland State University in US. She was appointed as an Assistant Professor at Biomedical Genetics Section, Department of Medicine, Boston University School of Medicine in 2009, where she currently holds an Adjunct Faculty position at Boston. She is now a Director and Head of Neurogenetics and Integrated Genomics, Andover Innovative Medicines Institute, Eisai Inc., a R&D unit for neurology and oncology in the US (since August, 2015 to date). She is responsible to develop novel therapeutic concepts driven by human genetics data and enabling the discovery and development of biomarkers and patient stratification markers for neurological R&D projects including Alzheimer’s disease. She continues on scientific research as an Adjunct Faculty at Boston University to identify genetic and genomics signatures using big data in consortia. She is an active member of many scientific advisory committees. She is the author of many papers published in internationally reputed journals. She has received many honors and awards including The American Society of Human Genetics (ASHG) and The International Genetic Epidemiology Society (IGES).
Her research focused on integrating large-scale clinical, genetic/genomics, and multi-omic data to identify novel diagnostic and therapeutic targets for Alzheimer’s disease and dementia. In academic setting at BU, she is interested in understanding and developing therapeutic concepts for neurological and eye diseases using genome-wide association, whole genome/exome sequencing, and RNA sequencing data. Currently, she is leading multiple projects in US and international consortia for APOE, tau, and HLA/immune genes related translational studies. In industry setting at Eisai Inc, she primarily focuses on dementia R&D projects.
Boffin Access Limited is committed to maintaining the integrity of the scholarly record to researchers. Therefore violation of professional ethical codes may lead to retract articles. Article(s) may be retracted if it is found to have serious flaws, reported misconduct research, constitute copyright infringement and plagiarism.
To help avoid the incorrect or misleading publications, please drop your message to
Enter your e-mail address to stay informed about published articles, issue releases and latest updates on journal activities.
We openly welcome feedback and constructive criticism. Your compliments, concerns and suggestions regarding our services will prove enormously helpful in making them even better.
Do you have an idea or suggestion that can influence the Open Access community? Send an email to: firstname.lastname@example.org
Copyright © 2020 Boffin Access Limited.